参考文献
1. hsueh pr., et al. chronological evolution of igm, iga, igg and neutralisation antibodies after infection with sars-associated coronavirus. clin microbiol infect. 2004 dec;10(12):1062-6.
2. lee n., et al. anti-sars-cov igg response in relation to disease severity of severe acute respiratory syndrome. j clin virol. 2006 feb;35(2):179-84.
3. wu lp., et al. duration of antibody responses after severe acute respiratory syndrome. emerg infect dis. 2007 oct;13(10):1562-4.
4. tang f., et al. lack of peripheral memory b cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study. j immunol. 2011 jun 15;186(12):7264-8.
5. wang h., et al. follow-up study on serological detection of anti-sars-cov igg/igm antibody and its significance. infectious disease information 2009:235-7.
6. guo x., et al. long-term persistence of igg antibodies in sars-cov infected healthcare workers. medrxiv 2020.02.12.20021386.
7. park wb., et al. kinetics of serologic responses to mers coronavirus infection in humans, south korea. emerg infect dis. 2015 dec;21(12):2186-9.
8. choe pg., et al. mers-cov antibody responses 1 year after symptom onset, south korea, 2015. emerg infect dis. 2017 jul;23(7):1079-1084.
9. payne dc., et al. persistence of antibodies against middle east respiratory syndrome coronavirus. emerg infect dis. 2016 oct;22(10):1824-6.
10. adams er., et al. antibody testing for covid-19: a report from the national covid scientific advisory panel. medrxiv 2020.04.15.20066407.
11. long qx., et al. antibody responses to sars-cov-2 in patients with covid-19. nat med. 2020 jun;26(6):845-848.
12. robbiani df., et al. convergent antibody responses to sars- cov-2 in convalescent individuals. nature. 2020 jun 18.
13. staines hm., et al. dynamics of igg seroconversion and pathophysiology of covid-19 infections. medrxiv 2020.06.07.20124636.
14. seow j., et al. longitudinal evaluation and decline of antibody responses in sars-cov-2 infection. medrxiv 2020.07.09.20148429.
15. wang k., et al. longitudinal dynamics of the neutralizing antibody response to sars-cov-2 infection. medrxiv 2020.07.14.20151159.
16. perreault j., et al. longitudinal analysis of the humoral response to sars-cov-2 spike rbd in convalescent plasma donors. biorxiv 2020.07.16.206847.
17. wajnberg a., et al. sars-cov-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. medrxiv 2020.07.14.20151126.
18. ibarrondo fj., et al. rapid decay of anti–sars-cov-2 antibodies in persons with mild covid-19. nejm. 2020; (published online july 21.)
19. lyer as., et al. dynamics and significance of the antibody response to sars-cov-2 infection. medrxiv 2020.07.18.20155374.
20. grandjean l., et al. humoral response dynamics following infection with sars-cov-2. medrxiv 2020.07.16.20155663.
21. yao xy., et al. neutralizing and binding antibody kinetics of covid-19 patients during hospital and convalescent phases. medrxiv 2020.07.18.20156810.
22. wu j., et al. sars-cov-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic covid-19. medrxiv 2020.7.21.20159178.
23. zhu fc., et al. immunogenicity and safety of a recombinant adenovirus type-5-vectored covid-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. lancet. 2020; (published online july 20.)
24. folegatti pm., et al. safety and immunogenicity of the chadox1 ncov-19 vaccine against sars-cov-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. lancet. 2020; (published online july 20.)
25. juno ja., et al. humoral and circulating follicular helper t cell responses in recovered patients with covid-19. nat med. 2020; (published online july 13..)
26. bert nl., et al. sars-cov-2-specific t cell immunity in cases of covid-19 and sars, and uninfected controls. nature.2020; (published online july 15.)
